Understanding how Mycoplasma genitalium resists antibiotics
Nitroimidazole susceptibility and mechanisms of resistance in Mycoplasma genitalium
This study is looking into how the bacteria Mycoplasma genitalium becomes resistant to antibiotics, with the hope of finding better treatment options for infections that can cause serious health problems like pelvic inflammatory disease and infertility.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10785739 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which the sexually transmitted bacterium Mycoplasma genitalium develops resistance to antibiotics, particularly focusing on its susceptibility to nitroimidazole compounds. The study aims to identify new treatment options for infections caused by this pathogen, which often leads to serious health issues such as pelvic inflammatory disease and infertility. By analyzing the genetic and biochemical factors contributing to antibiotic resistance, the research seeks to pave the way for more effective therapies. Patients may benefit from improved treatment options if successful.
Who could benefit from this research
Good fit: Ideal candidates for this research include adolescents and young adults who are diagnosed with Mycoplasma genitalium infections.
Not a fit: Patients with infections caused by other pathogens or those who do not have Mycoplasma genitalium may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new and effective treatments for Mycoplasma genitalium infections, potentially reducing complications such as infertility.
How similar studies have performed: While antibiotic resistance in Mycoplasma genitalium is a growing concern, this specific approach to identifying new treatment options is relatively novel and has not been extensively tested.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Wood, Gwendolyn — University of Washington
- Study coordinator: Wood, Gwendolyn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.